About atai Life Sciences
atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders.
We founded atai in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, as well as the emergence of therapies that previously may have been overlooked or underused, including psychedelic compounds and digital therapeutics.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights
November 14, 2023
Phase 2b study of RL-007 in CIAS patients continues to be on track to report data in 2H 2024 and data from the EMP-01 (MDMA derivative) Phase 1 study is anticipated to report out later this year. Phase 1 data of VLS-01 (a proprietary oral tran...
atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit
October 6, 2023
NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inau...
atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants
October 2, 2023
VLS-01, a proprietary oral transmucosal film (OTF) formulation of DMT, was well-tolerated with a favorable safety profilePharmacokinetic and pharmacodynamic data confirmed systemic delivery of DMT via the oral, transmucosal route at levels comp...